Regeneron Pharmaceuticals
As on 22 Apr, 2026 | 01:29 IST
| Open | 746.54 |
| Previous Close | 749.41 |
| Beta | 0.45 |
| High | 751.54 |
| Low | 735.00 |
| TTM EPS See historical trend | 44.38(-2.76% YoY) |
| 52 Week High | 821.11 |
| 52 Week Low | 476.79 |
| TTM PE See historical trend | 16.84(Low PE) |
| Mkt. Cap ($ Billion) | 82.05 |
| Dividend Yield | 0.46 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 749.44 |
| 10 | 754.11 |
| 20 | 755.56 |
| 50 | 764.21 |
| 100 | 761.24 |
| 200 | 674.95 |
Returns
| 1 Week | -1.06% | |
| 1 Month | 1.99% | |
| 3 Months | -0.19% | |
| YTD | -3.18% | |
| 1 Year | 33.02% | |
| 3 Years | -6.65% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 903.04 | -1.83 | 858.58 | 37.30 | 24.21 | 0.58 | 1,133.95/623.99 | -0.39 | Very Bearish |
| J&J | 226.14 | -1.97 | 544.95 | 21.08 | 10.73 | 2.16 | 251.71/146.13 | -4.00 | Bearish |
| AbbVie | 205.09 | 0.68 | 362.42 | 20.51 | 10.00 | 2.91 | 244.80/171.40 | 0.01 | Very Bearish |
| Merck | 112.57 | -3.87 | 285.10 | 12.55 | 8.97 | 3.12 | 125.14/73.35 | -1.40 | Bearish |
| Amgen | 344.86 | -1.51 | 185.37 | 15.78 | 21.85 | 2.95 | 391.23/261.50 | -0.87 | Very Bearish |
Market news
- Wall St ends mixed, notches weekly gains as investors parse Middle East negotiationsApril 11, 2026 8:53 AM
- Wall Street skids as Middle East turmoil fans inflation fearMarch 21, 2026 9:02 AM
- Wall Street closes lower, posts weekly loss as war on Iran fuels inflation worriesMarch 14, 2026 8:59 AM
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
About the company
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.